{"version":"1.0","type":"link","title":"Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.","author_name":"Xu Y 외","author_url":"https://prs-insight.online/author/Xu%20Y","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/101485","thumbnail_width":1200,"thumbnail_height":630}